The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 2:56 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #37. Oxygen Biotherapeutics Phyxius Pharma Assets

Acquirer: Oxygen Biotherapeutics (OXBT)
Acquiree: Phyxius Pharma Assets
Details: Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a developer of oxygen-carrying therapeutics, today announced the closing of its acquisition of certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), a significant unmet medical need. Pursuant to the previously announced Purchase Agreement, Oxygen Biotherapeutics acquired the exclusive rights to develop and commercialize levosimendan in North America, and will welcome three key Phyxius Pharma executives into its management team.

Oxygen Biotherapeutics is engaged in developing biotechnology products with a focus on oxygen delivery to specific target tissues. Co. is developing Oxycyte®, a systemic perfluorocarbon product for use in situations of acute ischemia, which is in clinical trial for the treatment of traumatic brain injury. Co. is also developing its topical products: Dermacyte® line of topical cosmetic products for skin health and other cosmetic benefits; and Wundecyte™ gel developed under a contract agreement with a lab in Virginia that is designed to be used as a wound-healing gel. Co. also has under development Vitavent™, an oxygen exchange fluid for facilitating the treatment of lung conditions.

Open the OXBT Page at The Online Investor »

Company Name: 
Tenax Therapeutics Inc
Website: 
www.oxygenbiotherapeutics.com
Sector: 
Biotechnology
 

Open the OXBT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 37 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.